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was £4,142 compared to £3,762 on PE. Overall tumour
response was 40.6% and 21.9% respectively and progres-
sion-free life years 0.575 and 0.358. Thus, the incremen-
tal cost-per-tumour-response of GC was £2,032 and the
incremental cost-per-progression-free-life-year £1,751. In
the final setting, the cost of GC was £5,084 and of MVP
£4,004. Overall tumour response was 54.0% and 36.7%
and one year survival 36% and 17% respectively. The in-
cremental cost-per-tumour-response of GC was £6,240
and the incremental cost-per-survivor-at-one-year was
£5,681. In extreme changes to underlying variables the
above ratios vary from dominance to a maximum of
£14,000. CONCLUSIONS: These results demonstrate
that Gemzar/cisplatin represents a relatively cost-effective
treatment for NSCLC with ratios comparable of below
those of therapies currently in use within the NHS.
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THE VALUE OF COMPLIANCE: EVIDENCE FROM 
TWO PATIENT COHORTS
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Epstein R
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OBJECTIVES: To identify the association between com-
pliance and the direct costs of care for two different clini-
cal patient cohorts. METHODS: Using administrative
claims data from Medstat MarketScan (tm) we assessed
the association between prescription drug compliance
and direct costs of care for two patient groups: a cohort
of non-Medicare patients diagnosed as diabetics (N 
9960) and second cohort of non-Medicare patients diag-
nosed with congestive heart failure (CHF)(N  935).
Since patients who are more compliant tend to be older
and have a greater number of comorbidities, and our goal
was to isolate the association between compliance and
medical care costs, we statistically controlled for differ-
ences in potential confounding variables using OLS re-
gression. Covariates included age, gender, comorbidity
indices (Chronic Disease Score and Charlson-Deyo), and
ICD-9-based severity of illness indicators. Compliance
was defined by calculating % days supply over a period
of one year. Compliance was then converted to 7 ordinal
categories in the regression model in order to identify
dose-response associations or threshold/inflection points.
RESULTS: Among diabetics, those who did not use any
prescription medication showed the lowest total costs of
care. However, among those patients who needed pre-
scription medication to manage their illness, increased
prescription drug costs among the most compliant are
more than offset by decreases in medical care costs, for
an estimated return on investment (ROI) of more than
two-fold. A similar, but stronger, pattern was found
among patients with CHF where the estimated ROI was
three-fold or greater. CONCLUSIONS: For some medi-
cal conditions, the additional costs associated with in-
creased compliance may be offset by lower medical costs,
resulting in an ROI greater than one.
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OBJECTIVES: Health care decision-makers need more
head-to-head drug comparison trials. Industry rarely
sponsors such studies, preferring placebo comparators.
We present an example of using meta-analysis for an in-
direct comparison of 2 drugs, with the results subse-
quently validated in a direct comparison trial. METH-
ODS: The drugs for comparison were abciximab and
tirofiban, both GPIIb/IIIa inhibitors used in patients with
acute coronary syndromes undergoing percutaneous cor-
onary interventions (PCI). A class effect has been as-
sumed for these agents, although they differ in molecular
structure and duration of action. We identified all pla-
cebo-controlled trials of each drug in PCI patients, and
meta-analysed the odds ratios (OR) for death or MI
(D/MI) at 30 days for each set of studies. These ORs were
then compared using a general linear model. RESULTS:
For D/MI at 30 days, the results of the meta-analysis of
the 6 abciximab studies [OR  0.52 (0.43, 0.63)] ap-
peared superior to the results of the 3 tirofiban studies
[OR  0.73 (0.55, 0.96)], although the differences did
not reach significance. In the model, a non-significant (p 
0.10) abciximab advantage was observed. The ratio of
the ORs of tirofiban/placebo and abciximab/placebo
meta-analyses was 1.4, suggesting a higher risk of D/MI
at 30 days for tirofiban relative to abciximab. After com-
pletion of these analyses, the results of a randomized
comparison trial of tirofiban vs. abciximab in PCI pa-
tients were announced (for D/MI at 30days OR  1.26,
p  0.04). The results demonstrated an advantage for ab-
ciximab, in keeping with our meta-analysis result. The
magnitude of the efficacy difference was similar to that
we had predicted. CONCLUSIONS: This is the first time
an indirect comparison of drugs using meta-analytic tech-
niques has been validated with a contemporaneous RCT.
This method should be used to predict results of direct
comparisons of drugs anytime such a trial is contem-
plated.
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OBJECTIVES: The cost of remifentanil, a short-acting
opiate, is approximately 10 times higher than fentanyl, a
